| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-03-25 | Laboratorios Farmacéuticos Rovi (Spain) Novartis Vaccines (Switzerland) |
vaccines against seasonal and pandemic influenza / seasonal and pandemic influenza | manufacturing commercialization/ distribution other |
See details |
| 2010-03-23 | GTx (USA) Ipsen (France) |
toremifene (selective estrogen receptor modulator, or SERM) / estrogen related side effects of androgen deprivation for advanced prostate cancer prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN) |
licensing commercialization/ distribution |
See details |
| 2010-03-23 | Integrated Biobank of Luxembourg (IBBL - Luxembourg) Life Technologies Corporation (USA) |
/ personalized medicine and genetic causes of disease | R&D other |
See details |
| 2010-03-17 | Evotec (Germany) Hypha Discovery (UK) |
natural product collection (MycoDiverse™ collection) | R&D other |
See details |
| 2010-03-16 | ImmunID (France) Roche (Switzerland) |
solutions in the field of immunomonitoring | R&D |
See details |
| 2010-03-12 | Ipsen (France) Rhythm Pharmaceuticals (USA) |
peptide therapeutics (melanocortin and ghrelin programs) / obesity, metabolic diseases, and gastrointestinal disorders | R&D licensing commercialization/ distribution development |
See details |
| 2010-03-12 | BioInvent International (Sweden) Human Genome Sciences (USA) |
therapeutic monoclonal antibodies | R&D manufacturing commercialization/ distribution development |
See details |
| 2010-03-11 | Evotec (Germany) Active Biotech (Sweden) |
small molecule modulators of an undisclosed priority biological target / immune disorders, cancer | R&D other |
See details |
| 2010-03-11 | Hemarina (France) Abcys (France) |
HEMOXCell® products for cell culture, HEMOXCell® Combo et HEMOXCell® Buffer This additive for cell culture media uses marine worm haemoglobin as an oxygenation additive (See http://www.biopharmaceutiques.com/en/article/97_1774.html). |
commercialization/ distribution |
See details |
| 2010-03-10 | Cellzome (UK) GSK (UK) |
selective small-molecule drug candidates identified on the basis of the Episphere™ technology platform / immunoinflammatory diseases | R&D licensing commercialization/ distribution development |
See details |
| 2010-03-10 | Transgene (France) Novartis (Switzerland) |
therapeutic vaccine TG4010 (MVA-MUC1-IL2) / non small cell lung cancer and other potential indications | manufacturing commercialization/ distribution development |
See details |
| 2010-03-09 | Lonza (Switzerland) Odyssey Thera (USA) |
Protein-fragment complementation assay technology | licensing |
See details |
| 2010-03-08 | Vernalis (UK) Paul Capital Healthcare (USA) |
Frovatriptan | other |
See details |
| 2010-03-06 | Ubiquigent (UK) Stemgent (USA) |
biological products and services generated by the SCottish Institute for ceLL Signalling | manufacturing other |
See details |
| 2010-03-03 | NicOx (France) Bausch & Lomb (USA) |
NCX 116 (previously PF-03187207- nitric oxide-donating prostaglandin F2-alpha analog) Last summer, Nicox has reacquired the full development and commercialization rights to PF-03187207 that have been licensed to Pfizer (See http://www.biopharmaceutiques.com/fr/tables/agreements_618.html) / glaucoma, ocular hypertension |
licensing commercialization/ distribution development |
See details |
